Last Updated: June 22, 2026

LINCOMYCIN Drug Patent Profile

Name: LINCOMYCIN Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Lincomycin patents expire, and when can generic versions of Lincomycin launch?

Lincomycin is a drug marketed by Arthur Grp, Gland, Micro Labs, Slate Run Pharma, Slayback, and Xgen Pharms. and is included in six NDAs.

The generic ingredient in LINCOMYCIN is lincomycin hydrochloride. There are eleven drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the lincomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lincomycin

A generic version of LINCOMYCIN was approved as lincomycin hydrochloride by XGEN PHARMS on June 4^th, 2015.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LINCOMYCIN?
What are the global sales for LINCOMYCIN?
What is Average Wholesale Price for LINCOMYCIN?

Summary for LINCOMYCIN

US Patents:	0
Applicants:	6
NDAs:	6
Drug Prices:	Drug price information for LINCOMYCIN
DailyMed Link:	LINCOMYCIN at DailyMed

Drug patent expirations by year for LINCOMYCIN

Recent Clinical Trials for LINCOMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Peter Doherty Institute for Infection and Immunity	Phase 4
Sunnybrook Health Sciences Centre	Phase 4
Berry Consultants	Phase 4

See all LINCOMYCIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for LINCOMYCIN

J01FF	Lincosamides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for LINCOMYCIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arthur Grp	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	212770-001	Mar 12, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Slate Run Pharma	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	216662-001	Dec 21, 2022		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Gland	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	215657-001	Sep 26, 2022	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Micro Labs	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	215082-001	Nov 8, 2021	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Xgen Pharms	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	201746-001	Jun 4, 2015	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Slayback	LINCOMYCIN HYDROCHLORIDE	lincomycin hydrochloride	INJECTABLE;INJECTION	063180-001	Apr 16, 1991		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

DrugChatter Q&A for LINCOMYCIN

Lincomycin hydrochloride supplier?
Lincomycin hydrochloride api manufacturer?
Pfizer lincomycin hydrochloride api?
Lincomycin hydrochloride bulk supplier?
Lincomycin hydrochloride manufacturer?

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.